epi’s Biotechnology Committee meets DG1 in Den Haag

On 29 November, the epi’s Biotechnology Committee and the DG1 of the European Patent Office had a significant and fruitful meeting took place at the EPO Den Haag, making a welcome return to epi BC/DG1 collaboration after a break of a few years. This gathering provided a platform for in-depth discussions on several vital specific topics impacting the biotechnology and pharmaceutical sectors. It provided also an essential opportunity for users to reconnect and engage in meaningful exchanges on a variety of pressing topics.

Among the key subjects addressed were the implications of plant biotechnology, the WIPO Treaty, and the ST.26 new standard for sequence listings. These discussions are vital as they set the groundwork for future developments and compliance in the industry. Additionally, the committee explored the complex issues surrounding the patentability of antibodies. Each of these topics has considerable relevance in the current landscape of biopharmaceutical innovation.

The meeting also featured insights from representatives and examiners of the European Patent Office, who shared updates on their new organizational structure. They outlined the evolution of their search and examination practices, emphasizing their ongoing commitment to enhancing best practices and improving quality.

This exchange of information not only fostered collaboration but also ensured that all users have with the latest knowledge to navigate the evolving landscape of patent law and biotechnology. Overall, the meeting fostered a collaborative atmosphere, paving the way for ongoing dialogue and cooperation between the epi’s Biotechnology Committee and the European Patent Office.